Schrodinger SDGR Drug discovery — Revenue recognized with milestones

Similar metrics at other companies

ZYMEMilestone revenue — Research and development collaborations

$0-100%

ZYMEResearch, Development and Commercial Milestones — Research and development collaborations (note 11)

$0—

AXSMMilestone Revenue — Revenue

$500K—

TBPHLicensing And Milestone — Revenue

$8.13M—

INCYMilestone and contract revenues — Total revenues

$17M—

ZYMEResearch Milestone — Research and development collaborations (note 11)

$8.75M—

Other financials

Income statement

See full

Revenue$58.6M-1.6%

Gross profit$29.5M-5.1%

Operating income-$48.8M+4.1%

Net income-$60.0M-0.4%

EPS (diluted)-$0.81+1.2%

Balance sheet

See full

Cash & equivalents$267.7M-20.7%

Total debt$107.0M-7.9%

Total equity$313.5M-16.1%

Total assets$634.2M-14.6%

Cash flow

See full

Operating cash flow-$14.8M-110%

CapEx$2.5M+321%

Free cash flow-$17.3M-112%

Valuation

See full

Market cap$1.15B-23.7%

Enterprise value$984.71M-23.1%

P/S4.5×-2.0×

Profitability

See full

Gross margin55.3%-7.3pp

Operating margin-64.7%-12.0pp

Net margin-68.5%—

FCF margin9.6%+5.1pp

Returns & leverage

See full

Return on equity-45.7%—

Debt / equity0.3×0.0×

Current ratio2.7×-0.7×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept sdgr:RevenueRecognizedForMilestonePayment.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's drug discovery — revenue recognized with milestones.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Schrodinger's drug discovery — revenue recognized with milestones?: Schrodinger (SDGR) reported drug discovery — revenue recognized with milestones of $0 in Q1 2026.
What does drug discovery — revenue recognized with milestones mean?: This reflects the portion of total revenue derived from the successful achievement of predefined research or clinical development milestones. It highlights the company's success in advancing its drug discovery programs toward commercialization.